Supplemental Table S6. Hazard Ratios for the Development of Type 2 Diabetes in the Metabolically Healthy Obese Population Considering the TyG Index

	Definition of metabolic health			
	ATP-III	Wildman	Karelis	HOMA
Unadjusted HRs (95% CI)				
MHNO	1.00 (reference)	1.00 (reference)	1.00 (reference)	1.00 (reference)
MUNO	5.21 (4.18-6.49)	6.12 (4.82–7.78)	2.63 (2.11-3.28)	2.44 (1.93-3.08)
MHO				
Low TyG	1.78 (1.33–2.39)	2.08 (1.42-3.04)	2.02 (1.47-2.76)	1.43 (1.08–1.91)
High TyG	3.59 (2.57-5.01)	4.78 (2.86-8.02)	6.25 (4.19–9.31)	3.95 (3.09-5.04)
MUO	8.96 (7.39–10.87)	9.99 (7.96–12.52)	5.55 (4.55-6.76)	5.50 (4.59-6.59)
Adjusted HRs (95% CI) <sup>a</sup>				
MHNO	1.00 (reference)	1.00 (reference)	1.00 (reference)	1.00 (reference)
MUNO	3.69 (2.91-4.67)	4.08 (3.16-5.28)	1.64 (1.29–2.07)	1.98 (1.56–2.51)
МНО				
Low TyG	1.09 (0.79–1.50)	1.30 (0.87–1.95)	1.01 (0.72–1.41)	0.84 (0.62–1.15)
High TyG	2.28 (1.58-3.27)	3.27 (1.91–5.57)	3.39 (2.22–5.17)	2.12 (1.61–2.79)
MUO	4.63 (3.57-6.00)	5.07 (3.79-6.78)	2.26 (1.75-2.93)	2.72 (2.13-3.46)

TyG, triglyceride glucose; ATP-III, Adult Treatment Panel III; HOMA, homeostatic model assessment; HR, hazard ratio; CI, confidence interval; MHNO, metabolically healthy non-obese; MUNO, metabolically unhealthy non-obese; MHO, metabolically healthy obese; MUO, metabolically unhealthy obese.

<sup>a</sup>Adjusted for age, sex, waist circumference, systolic blood pressure, drinking, smoking, exercise, family history of diabetes, alanine aminotransferase, gamma-glutamyl transferase, high-sensitivity C-reactive protein, and low-density lipoprotein cholesterol.